The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Vicente E. Torres

Division of Nephrology and Hypertension

Department of Internal Medicine

Mayo Clinic




Name/email consistency: high



  • Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, USA. 2001 - 2012
  • Mayo Clinic, 200 First St SW, Rochester, MN 55905. 2012
  • Mayo Clinic College of Medicine, Rochester, Minnesota, USA. 2009 - 2011
  • Division of Nephrology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, USA. 2004 - 2010
  • Mayo Clinic College of Medicine, Eisenberg S33B, Nephrology, 200 First St SW, USA. 2006
  • Department of Nephrology, Mayo Foundation Clinic, Rochester, Minn., USA. 1997 - 2004
  • Mayo Foundation, Rochester, Minnesota, USA. 2004


  1. Tolvaptan in patients with autosomal dominant polycystic kidney disease. Torres, V.E., Chapman, A.B., Devuyst, O., Gansevoort, R.T., Grantham, J.J., Higashihara, E., Perrone, R.D., Krasa, H.B., Ouyang, J., Czerwiec, F.S. N. Engl. J. Med. (2012) [Pubmed]
  2. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Wang, X., Ye, H., Ward, C.J., Chu, J.Y., Masyuk, T.V., Larusso, N.F., Harris, P.C., Chow, B.K., Torres, V.E. Am. J. Physiol. Renal Physiol. (2012) [Pubmed]
  3. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Irazabal, M.V., Huston, J., Kubly, V., Rossetti, S., Sundsbak, J.L., Hogan, M.C., Harris, P.C., Brown, R.D., Torres, V.E. Clin. J. Am. Soc. Nephrol (2011) [Pubmed]
  4. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Torres, V.E., Grantham, J.J., Chapman, A.B., Mrug, M., Bae, K.T., King, B.F., Wetzel, L.H., Martin, D., Lockhart, M.E., Bennett, W.M., Moxey-Mims, M., Abebe, K.Z., Lin, Y., Bost, J.E. Clin. J. Am. Soc. Nephrol (2011) [Pubmed]
  5. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Torres, V.E., Boletta, A., Chapman, A., Gattone, V., Pei, Y., Qian, Q., Wallace, D.P., Weimbs, T., Wüthrich, R.P. Clin. J. Am. Soc. Nephrol (2010) [Pubmed]
  6. Treatment strategies and clinical trial design in ADPKD. Torres, V.E. Adv. Chronic. Kidney. Dis (2010) [Pubmed]
  7. A case for water in the treatment of polycystic kidney disease. Torres, V.E., Bankir, L., Grantham, J.J. Clin. J. Am. Soc. Nephrol (2009) [Pubmed]
  8. Vasopressin in chronic kidney disease: an elephant in the room? Torres, V.E. Kidney Int. (2009) [Pubmed]
  9. Autosomal dominant polycystic kidney disease: the last 3 years. Torres, V.E., Harris, P.C. Kidney Int. (2009) [Pubmed]
  10. Role of vasopressin antagonists. Torres, V.E. Clin. J. Am. Soc. Nephrol (2008) [Pubmed]
  11. Vasopressin antagonists in polycystic kidney disease. Torres, V.E. Semin. Nephrol. (2008) [Pubmed]
  12. Update on autosomal dominant polycystic kidney disease. Torres, V.E., Rossetti, S., Harris, P.C. Minerva Med. (2007) [Pubmed]
  13. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Torres, V.E., King, B.F., Chapman, A.B., Brummer, M.E., Bae, K.T., Glockner, J.F., Arya, K., Risk, D., Felmlee, J.P., Grantham, J.J., Guay-Woodford, L.M., Bennett, W.M., Klahr, S., Meyers, C.M., Zhang, X., Thompson, P.A., Miller, J.P. Clin. J. Am. Soc. Nephrol (2007) [Pubmed]
  14. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. Torres, V.E., Harris, P.C. J. Intern. Med. (2007) [Pubmed]
  15. Autosomal dominant polycystic kidney disease. Torres, V.E., Harris, P.C., Pirson, Y. Lancet (2007) [Pubmed]
  16. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Torres, V.E., Harris, P.C. Nature Clinical Practice. Nephrology (2006) [Pubmed]
  17. Vasopressin antagonists in polycystic kidney disease. Torres, V.E. Kidney Int. (2005) [Pubmed]
  18. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Torres, V.E., Wang, X., Qian, Q., Somlo, S., Harris, P.C., Gattone, V.H. Nat. Med. (2004) [Pubmed]
  19. Therapies to slow polycystic kidney disease. Torres, V.E. Nephron Exp. Nephrol. (2004) [Pubmed]
  20. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Torres, V.E., Sweeney, W.E., Wang, X., Qian, Q., Harris, P.C., Frost, P., Avner, E.D. Kidney Int. (2004) [Pubmed]
  21. Autosomal dominant polycystic kidney disease. Torres, V.E., Harris, P.C. Nefrologia (2003) [Pubmed]
  22. Vascular expression of polycystin-2. Torres, V.E., Cai, Y., Chen, X., Wu, G.Q., Geng, L., Cleghorn, K.A., Johnson, C.M., Somlo, S. J. Am. Soc. Nephrol. (2001) [Pubmed]
  23. Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Torres, V.E., Cowley, B.D., Branden, M.G., Yoshida, I., Gattone, V.H. Exp. Nephrol. (2001) [Pubmed]
  24. Renal concentration of alpha-tocopherol: dependence on gender and lack of effect on polycystic kidney disease in Han:SPRD rats. Torres, V.E., Bengal, R.J., Nickander, K.K., Grande, J.P., Low, P.A. Am. J. Kidney Dis. (1998) [Pubmed]
  25. Inherited renal neoplasms. Torres, V.E., Bjornsson, J., Zincke, H. J. Nephrol. (1998) [Pubmed]
  26. Renal manifestations of tuberous sclerosis complex. Torres, V.E., Zincke, H., King, B.K., Bjornsson, J. Contrib. Nephrol (1997) [Pubmed]
WikiGenes - Universities